Identifying patients at high risk for acute kidney injury (AKI) during hospitalization among patients admitted with severe alcoholic hepatitis (AH) is an unmet clinical need. We performed a multicentric prospective cohort study using data from 4 different cohorts on well-characterized patients hospitalized with severe AH. Data collected on 773 AH patients from 4 cohorts across the globe were randomly split into test (n = 390) and validation (n = 383) cohorts. We found that 32% of the patients developed inpatient AKI in the test cohort. Approximately 60% of patients met criteria for systemic inflammatory response syndrome (SIRS) at admission. Hepatic encephalopathy, SIRS, and Model for End-Stage Liver Disease score at admission predicted inpatient AKI with odds ratios of 3.86, 2.24, and 1.14, respectively. The AKI risk score developed using these predictors stratified risk of inpatient AKI to low (score <3), moderate (3-4), and high (>4). These findings were replicated in the validation cohort. In the whole study cohort, patients with AKI had a lower 90-day survival (53% versus 77%; P < 0.001). Those with AKI risk score of >4 had significantly lower 90-day survival as compared with those with risk scores between 3 and 4 and <3 (47% versus 68% versus 88%; P < 0.001). In conclusion, AKI occurs frequently in AH patients and negatively impacts short-term mortality. The AKI risk score is useful in identifying patients at high risk for inpatient AKI and may be useful for developing new therapeutic strategies to prevent AKI in patients with AH.
Alcoholic hepatitis (AH) is a clinical syndrome characterized by rapid onset or worsening of jaundice, liver-related complications, and features of systemic inflammatory response syndrome (SIRS). (1) Despite improvements in supportive care, AH continues to have a short-term mortality of 30%-40% within 3 months from presentation. (2) (3) (4) Causes of mortality include liver failure, complications of portal hypertension, infection, and renal failure. A hospital admission with AH contributes to a significant health and economic burden with the average length of hospitalization of 6.1 days with a cost of about $46,264. (5) Of the available scoring systems, Maddrey's discriminant function score, Model for End-Stage Liver Disease (MELD) score, and Lille score are the most frequently used in clinical practice. Among patients with cirrhosis, the development of acute kidney injury (AKI) is one of the major determinants of clinical outcomes. (6) (7) (8) (9) However, data on the occurrence and predictors of AKI specific to patients with AH are scanty. (10) (11) (12) The negative impact of AKI on shortterm survival in AH patients underscores the need for early recognition of patients at risk for AKI, as a basis for targeting them for strategies to prevent it. (10, 12) The degree of liver failure and the occurrence of SIRS in AH patients potentially contribute to the development of AKI. (4, 12) Moreover, patients with AH are frequently infected at admission and may be associated with AKI in patients with advanced liver disease. (12, 13) Although initial reports have shown that pentoxifylline could protect AH patients with AKI, more recent studies have not confirmed this beneficial effect. (14) The development of preventive and therapeutic strategies for AKI in patients with AH is hampered by the lack of predictive and mechanistic studies. Identifying patients at high risk for developing AKI could favor translational studies that ultimately identify the main determinants of renal derangement in this clinical setting. The current study was aimed at addressing this knowledge gap. Data on prospectively developed cohorts on well-characterized AH patients from 4 centers across the world were pooled to analyze the frequency of inpatient AKI, its impact on patient survival, and clinical variables at admission associated with inpatient AKI. The longterm goal of this study is to develop strategies and interventions aiming to prevent AKI as a basis for improving outcomes of patients with AH.
Patients and Methods

STuDY DESIGN AND pOpuLATION
We performed a prospective cohort study on well-characterized patients hospitalized with severe AH using data from 4 different centers in the United States, Europe, and India. The diagnosis of AH was determined using the standardized definition, as described later. Institutional review boards from each center approved the study. For patients with multiple admissions with AH, only data from the index episode were used in the analysis.
DATA COLLECTION
DEFINITIONS
AH was defined using the following criteria:
1. Alcohol use of >60 g/day in men and >40 g/day in women for >5 years. 2. Last drink within 3 weeks of admission. 3. Serum bilirubin >3 mg/dL. 4. Elevated transaminases >50 and <400 IU/L. 5. Aspartate transaminase to alanine transaminase ratio of >2:1. 6. Exclusion of other concomitant liver disease. (15) Cirrhosis was defined based on clinical/imaging criteria and/or biopsy when available.
Infection was defined using the standard proposed criteria. (16) Inpatient AKI was defined using the AKI Network criteria with an increase in serum creatinine >50% or an increase of ≥0.3 mg/dL from admission value. (17, 18) SIRS was defined as the presence of 2 or more of the following criteria:
ORIGINAL ARTICLE | 1657 1 . Heart rate ≥90 beats per minute (bpm). 2. Temperature ≥38°C or ≤36°C. 3. WBC count ≥12,000 or ≤4000/mcL. 4. Respiratory rate ≥20 breaths/minute. (19) HE is defined uniformly as an altered mental status with compatible physical examination (positive asterixis without focal neurological findings) after excluding other confounders, including ethanol withdrawal and septic encephalopathy.
STATISTICAL ANALYSIS
The complete cohort of patients was randomly assigned to a test or validation cohort, using a split-sample validation technique from predefined commands of the statistical software. Within each cohort, a comparative study between patients with and without AKI was performed. Continuous variables were described as mean ± standard deviation (SD), and categorical variables were described as counts and proportions. Normality was evaluated by the Kolmogorov-Smirnov test, and comparisons between groups were performed using the Student t test or Mann-Whitney U test, when appropriate. Differences between categorical variables were assessed by chi-square or Fisher's exact tests.
In the test cohort, the association and predictive value of factors significantly different between groups were analyzed by logistic regression to obtain odds ratios (ORs) on variables at admission associated with inpatient AKI (univariate analysis). P values for these univariate analyses were not corrected for multiple testing because those tests were taken as exploratory. A logistic regression model was developed based on predictors that were most significant in the univariate analysis. Variables that were statistically significant (P ≤ 0.05) were entered first into a 1-step multivariate logistic regression and then manually confirmed by an elimination variable selection procedure in a 1-by-1 fashion (multivariate logistic regression) following a backward procedure. Variables on univariate analysis with P <0.15 were entered into the model. We aim to avoid overfitting of the prognostic models, so we defined that the ratio of the candidate prognostic variables to the number of observed events (AKI) was less than 1:10. In addition, to evaluate the overall significance of the models (discrimination), we chose the Hosmer-Lemeshow test because it is considered more robust than the traditional chi-square test. (20) For the calibration (ie, how close the variables included in a given model are to the real underlying probability), Nagelkerke's coefficient of determination (R N2 ) was used. (21) The R N2 values range between 0 and 1: As this value approaches 1, the better the fitness of the model. It thus served as a measure of explained variation and to identify overoptimistic models. Finally, in order to avoid collinearity, we included the MELD score in the multivariate models given that this scoring system included all biochemical variables with statistical significance identified at the univariate analysis. Receiver operating characteristic (ROC) curves were used to calculate the area under the receiver operating characteristic curve (AUROC) for each, and we chose the model that performed best in the clinical setting.
The final model was then transformed into an equation, generating a value (the AKI risk score) that was then used to divide the patients into 3 groups (<3, 3-4, and >4), stratifying the risk for AKI. We chose these cutoffs based on the sensitivity and specificity analysis of each point based on the following results of the AUROC analysis in the test cohort: at a cutoff of <3 points, sensitivity 93.5% and specificity of 14.1%; at a cutoff of 3-4 points, sensitivity 67.9% and specificity of 38.2%; and at a cutoff of >4 points, sensitivity 51.4% and specificity of 76.7%. We have included this information in the Supporting Materials. Finally, the AKI risk score was applied to the validation cohort, performing a ROC and AUROC analysis as the basis of validating the developed AKI risk score. KaplanMeier curves were generated for 90-day survival comparing patients with and without AKI and comparing AKI risk score subgroups. Patients surviving more than 90 days from the initial hospitalization date were censored.
To take into account the center-based differences between the randomly split test and validation cohorts, the regression models were developed on 3 separate randomly split test and validation cohorts.
SuBGROup ANALYSIS
To minimize the effect of patients who may have had AKI on admission, a subgroup analysis limited to patients with admission serum creatinine below 1.5 mg/dL was performed. Data were analyzed using the IBM SPSS statistical package, version 21.0 (IBM Corp., Armonk, NY). P < 0.05 was considered statistically significant for all tests performed.
Results
STuDY pOpuLATION
Data were collected both on 773 patients, including age 47 ± 10 years, 82% males, 46% Caucasians, 61% with underlying cirrhosis, mean MELD score 24 ± 7, and mean admission serum creatinine 1.15 ± 1.28 mg/dL, and also on 4 cohorts at academic referral centers in the United States, Europe, and India. The baseline characteristics comparing these 4 cohorts differed for age, sex, ethnicity, proportion of underlying cirrhosis, SIRS, and mean MELD score (Supporting Table 1 ). For example, all of the patients in cohort 2 were Asian males compared with 66%-73% males and 76%-95% Caucasians in the other 3 cohorts. Similarly, the 4 centers were different for the proportion of patients with SIRS, infection, underlying cirrhosis, and liver disease complications (Supporting Table 1 ). Baseline characteristics were similar comparing the test cohort (n = 390) and the validation cohort (n = 383; Supporting Table 2 ) and comparing these cohorts separately among patients with and without AKI (Supporting Table 3A,B) . Furthermore, patients from each center were equally distributed to the test and validation cohorts. For example, out of 390 of 773 (50.5%) patients in the test cohort, 56 of 117 (48%) were included from cohort A, 181 of 365 (49.6%) from cohort B, 123 of 324 (38%) from cohort C, and 30 of 67 (45%) from cohort D. The remaining patients were in the validation cohort.
DEvELOpMENT OF AKI IN THE TEST COHORT
Of 390 patients in the test cohort, 126 (32%) developed AKI during admission. Patients who developed AKI were more likely to have presence of HE (36% versus 13%; P < 0.001) and SIRS (72% versus 55%; P = 0.001) at admission and to develop infections during hospitalization (50% versus 30%; P < 0.001) than those without AKI. Patients with AKI also had a higher MELD score (28 versus 22; P < 0.001) with higher baseline values of serum bilirubin, serum creatinine, and INR (Table 1) . Although there were differences within each cohort comparing AKI and without Table 2 ) did not show any differences. A total of 235 (60%) patients had SIRS at the time of admission with 62% meeting the criteria on heart rate, 26% on respiratory rate, 21% on temperature, and 65% on WBC count (Supporting Table 2 ).
pREDICTORS OF AKI AND AKI RISK SCORE
On univariate analysis, 4 admission variables-HE, SIRS, infection, and MELD score-predicted the development of AKI during admission. Respiratory rate, temperature, and WBC count were the components of SIRS associated with the development of AKI during hospitalization (Table 2) . Multivariate logistic regression analysis revealed 2 models associated with development of AKI during hospitalization ( 
vALIDATION OF THE AKI RISK SCORE
The validation cohort included 383 patients, of which 122 (32%) patients developed AKI during hospitalization. Like the test cohort patients, patients with AKI were more likely to have HE (30% versus 13%; P < 0.001) and SIRS at admission (66% versus 49%; P = 0.001) and to develop infections during hospitalization (39% versus 25%; P = 0.004) than those without AKI. Patients with AKI also had a higher MELD score (28 versus 22; P < 0.001) with higher baseline values of serum bilirubin, serum creatinine, and INR (Table 1) . A total of 207 (54%) patients had SIRS at the time of admission with 56% meeting criteria on heart rate, 26% on respiratory rate, 18% on temperature, and 64% on WBC count (Supporting Table 2 ). The AKI risk score generated from the test cohort (Table 4) showed an AUROC of 0.74 (95% CI, 0.69-0.80; P < 0.001) when tested on the validation cohort (Fig. 1B) . Patients were stratified into 3 different risk subgroups with inpatient AKI in 41 of 57 (72%) patients with a score of >4 (high risk), 35 of 101 (35%) patients with a score of 3-4 (intermediate risk), and 36 of 181 (20%) patients with a score of <3 (low risk; P < 0.001; Fig. 2B ).
IMpACT OF AKI ON pATIENT SuRvIvAL
Ninety-day follow-up was available for 756 (98%) patients. Of these, 235 (31%) patients developed AKI during hospitalization. Survival at 90 days was lower among patients with inpatient AKI compared with those without (55% versus 78%; P < 0.001; Fig. 3 ). Kaplan-Meier survival curves comparing subgroups of AKI risk score (<3 versus 3-4 versus >4) showed 90-day survival to be 47%, 68%, and 88%, respectively (log-rank P < 0.001; Fig. 4 ).
SuBGROup ANALYSIS
A total of 659 patients were included in the subgroup analysis after excluding 114 patients with admission creatinine >1.5 mg/dL. These patients were split into test (n = 332) and validation (n = 327) cohorts, and the findings were similar and consistent with those in the 
Discussion
Here are the main findings of our study:
1. Inpatient AKI occurred in a third of patients admitted with an episode of severe AH. 2. Risk score derived from admission parameters of HE, MELD score, and SIRS predicts the risk of inpatient AKI. 3. Inpatient AKI score and risk score are associated with negative outcomes and survival at 90 days.
AKI is reported in approximately 20% of hospitalized patients with liver cirrhosis. (18, 22) A higher prevalence of 33% of inpatient AKI among severe AH patients in our study is similar to 2 earlier reports of 28% and 33%. (10, 12) As in AH patients, AKI occurs frequently among hospitalized patients with cirrhosis and acute-on-chronic liver failure (ACLF). (9, 23, 24) SIRS was an important predictor of AKI in our study, which is similar to earlier reports among patients with severe AH. (4, 10, 12) Patients with AH and ACLF are prone to the development of bacterial and fungal infections because of their immune-compromised state from cirrhosis; further immune paralysis with AH and ACLF, resulting from ineffective compensatory response to ongoing cytokine storm; peripheral cellular abnormalities with their inability to phagocytose and kill microorganisms; and the use of concomitant medications, especially corticosteroids. (4, 23, (25) (26) (27) (28) (29) (30) The Sequential Organ Failure Assessment and sepsis 3 scores have been used quite accurately in patients with sepsis and conditions at high risk for infections, including those with AH. However, we did not use these scores in our regression modeling, recognizing that SIRS in AH patients can also occur without associated infection (sterile SIRS) and that it is mediated by damage-associated molecular patterns including cell organelles and high-mobility group box 1 protein, which are released from ongoing cell death. (23, 31, 32) This was observed in this study also with only 46% of patients in the test cohort and 39% of patients in the validation cohort with SIRS who had documented infection.
SIRS from any mechanism worsens the portal hypertension and splanchnic vasodilation in these patients, resulting in reduced effective circulatory blood volume renal blood flow, which sets the stage for AKI. (4, 23) Intuitively, beta-blocker therapy in severe AH patients was shown to be associated with AKI, likely from the same mechanism. (11) Infection associated with AH can directly damage the renal tubules, causing acute tubular necrosis and AKI. Association of AKI with negative outcomes and worse survival in our study is like other reports involving patients with cirrhosis, ACLF, and severe AH. (9, 10, 12, 18, 22, 24) To our knowledge, ours is the first study developing a novel clinical score for use in routine practice to predict the risk of AKI at admission among patients hospitalized for severe AH. Other strengths of the study are large sample size; multicenter, international prospective cohorts; well-characterized AH patients using uniform definitions across the centers; and statistical design with internal validation of results. However, there may have been patients with AKI at admission, and in these patients, we may be assessing AKI progression and not its occurrence. In a recently reported study, baseline serum creatinine was directly proportional to the risk of AKI among hospitalized patients with cirrhosis. (8) However, to minimize the effect of baseline creatinine and possible AKI at admission, a subgroup analysis after excluding patients with admission creatinine >1.5 mg/dL was performed, which showed similar results as in the original cohort. Furthermore, a lack of data from each respective center on control PT, specific pharmacologic treatment of AH, and beta-blocker use limited the assessment of these variables. The clinical risk score developed in this study would potentially be useful for physicians, gastroenterologists, and hepatologists taking care of patients admitted with severe AH. Such a score provides a way to risk stratify patients for occurrence of AKI and to adopt preventative strategies to decrease the AKI risk and improve their outcomes. In conclusion, AKI occurs frequently in hospitalized patients with AH and is a predictor of mortality. AKI risk score using the 3 variables present at admission of SIRS, HE, and MELD score stratifies the risk of inpatient AKI. Future clinical trials are suggested to examine the benefit of preventative interventions such as intravenous albumin administration, especially among patients at high risk for AKI, as determined using the AKI risk score developed in this study. Translational studies are also suggested to develop biomarkers for early diagnosis of AKI and to identify molecular mediators of occurrence and reversibility of AKI.
